Kalaris Therapeutics Inc. Common Stock (KLRS)
Stock · NASDAQ · Health Care
$2as of 10/16/2026
Price chart
Active signals
KLRS Signal Track Record
How signals performed across all stocks →What KLRS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -4.5% | 46% | October 2, 2026 |
| Bollinger Band Breakout | 24 | -7.7% | 25% | February 19, 2026 |
| Bollinger Band Breakdown | 22 | -6.1% | 41% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -7.0% | 43% | April 1, 2026 |
| Any 20-session window (baseline) | -2.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular ret…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 20
- Website
- kalaristx.com/
Fundamentals
- 1-day range
- $2.36$2.55
- Market cap
- $99.69M
- P/E (trailing)
- —
- P/E (forward)
- -1.43
- EPS (trailing)
- $-2.09
- Dividend yield
- —
- Beta
- 0.43
- Avg. volume
- 254.4K
Forecasts
7 analyst ratings
Kalaris Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KLRSKalaris Therapeutics Inc. Common Stock$2▼ 8.68%Market cap $99.69MP/E —$2.35$11.88
- CGTXCognition Therapeutics Inc. Common Stock$0.73▼ 0.41%Market cap $101.13MP/E —$0.5501$2
- PTHSPelthos Therapeutics Inc. Common Stock$20.15▼ 0.54%Market cap $102.36MP/E —$18.19$37.5
- BDTXBlack Diamond Therapeutics Inc. Common Stock$1.72▼ 1.15%Market cap $110.02MP/E —$1.6$4.94
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $2 | ▼ 8.68% | $2.35$11.88 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $0.73 | ▼ 0.41% | $0.5501$2 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $20.15 | ▼ 0.54% | $18.19$37.5 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $1.72 | ▼ 1.15% | $1.6$4.94 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/30/2026
Insider Activity
Insider Actions →- Vandekop Amy O'Leary · August 27, 2026 · Grant10.0K
- KEATING LAURIE · August 1, 2026 · Grant18.0K
- Bayko Liisa Ann · July 20, 2026 · Grant220.0K
- Napoleone Ferrara · June 3, 2026 · Grant9.0K
- Dybbs Michael · June 3, 2026 · Grant9.0K
- Jovan-Embiricos Morana · June 3, 2026 · Grant9.0K
- Hallal David · June 3, 2026 · Grant9.0K
- ADAMIS ANTHONY P · June 3, 2026 · Grant9.0K
- Srinivas Akkaraju · June 3, 2026 · Grant9.0K
- Leone D. Patterson · June 3, 2026 · Grant9.0K
- Srinivas Akkaraju · May 20, 2026 · J4.5K
- Srinivas Akkaraju · May 20, 2026 · J14.9K
- Srinivas Akkaraju · May 20, 2026 · J66.9K
- Srinivas Akkaraju · May 20, 2026 · Buy244.3K @ $4.83
Institutional Ownership
March 31, 2026
- Total shares held
- 18.54M
- Total value held
- $106.90M
- Institutional holders
- 55
- Unknown12.95M
- Unknown1.30M
- Unknown700.0K
- Unknown572.7K
- Unknown435.8K
- Unknown360.0K
- Unknown295.8K
- Unknown255.3K
- Unknown135.6K
- Unknown118.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI
Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.